MEDICLIN AG
ISIN: DE0006595101
WKN: 659510
28 March 2025 10:24AM

EQS-News: MEDICLIN ends successful 2024 financial year

MEDICLIN AG · ISIN: DE0006595101 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2108024

EQS-News: MEDICLIN AG / Key word(s): Annual Report/Miscellaneous
MEDICLIN ends successful 2024 financial year

28.03.2025 / 10:24 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, March 28, 2025
MEDICLIN ends successful 2024 financial year
 
MEDICLIN Aktiengesellschaft (ticker: MED; WKN 659 510) today published its annual report for the year 2024. The group generated sales of EUR 748.8 mill., which corresponds to an increase of 2.6 % compared to the previous year (2023: EUR 730.1 mill.). MEDICLIN the highest sales in thus achieved the company's history to date. At EUR 53.5 mill., the group operating result was EUR 40.8 mill. higher than the previous year's result (2023: EUR 12.7 mill.), which was heavily burdened by goodwill amortisation in the acute segment.

Dr Joachim Ramming, CEO of MEDICLIN, comments: "The development of the last financial year confirms that the strategic focus on our core competence, rehabilitation, is the right decision for the future of MEDICLIN. The acquisition of the Reha-Klinik am Sendesaal at has also brought us another step closer to our goal of becoming Germany's leading rehabilitation provider."

MEDICLIN's operating performance is emphasised even more clearly by an adjusted view of consolidated group sales and the group operating result. "Changes in the scope of consolidation, such as the acquisition of the Reha-Klinik am Sendesaal and the sale of the former MEDICLIN Herzzentrum Coswig, distort sales growth and group operating result on a relative basis", comments Tino Fritz, CFO of MEDICLIN, and adds: "Adjusted for all special effects, we were able to increase consolidated group sales by over 8 % and group operating result by over 70 %."

Developments in the segments

In the post-acute segment, sales totalled EUR 485.4 mill., up EUR 34.2 mill. or 7.6 % on the previous year. Sales do not include any significant services from the protective shield, whereas the previous year's figure included EUR 7.4 mill. The operating result for the post-acute segment of EUR 52.2 mill. corresponds to a decrease of EUR 0.5 mill. or 0.8 % compared to the previous year (2023: EUR 52.7 mill.). Adjusted for all special effects, the increase in the segment operating result corresponds to EUR 10.1 mill. or 24.7 %.

Thomas Piefke, COO of MEDICLIN, comments: "We are very satisfied with the development of our core segment post-acute, but we must not rest on our laurels. The challenging environment and the shortage of skilled labour continue to pose challenges for our industry. We are therefore continuing to work on the digitalisation and ambulantisation of our services and are consistently pursuing our strategy.”

Sales in the acute segment totalled EUR 234.8 mill. (2023: EUR 254.0 mill.). The decline in sales is mainly due to the sale of the former MEDICLIN Heart Centre Coswig. When the acute segment is adjusted for all special effects, an adjusted increase of 8.7% was achieved. An operating result of EUR -0.6 mill. was achieved in the acute segment (previous year: EUR -39.9 mill.). The segment's operating result in 2023 was significantly impacted by the one-off effect of goodwill amortisation for three facilities - totalling EUR 33.1 mill. When considering the segment operating result adjusted for all special effects, this corresponds to an adjusted increase of EUR 9.1 mill.

Sales in the nursing care segment rose to EUR 23.4 mill. in the reporting year (2023: EUR 21.3 mill.), while the segment operating result reached EUR 0.2 mill., as in the previous year.

Sales in the Service segment increased by EUR 13.3 mill. to EUR 94.6 mill. At EUR 1.7 mill., the segment operating result was EUR 2.0 mill. higher than in the previous year (2023: EUR -0.3 mill.).

Further information on developments in the segments and detailed reconciliation tables for adjusted sales and operating results can be in the 2024 Annual Report under Investor Relations. MEDICLIN has decided to stop printing its annual report in order to make a contribution to environmental protection and protect resources.


Outlook 2025

The stable utilisation rate and the adjustments to MEDICLIN's portfolio make the Management Board optimistic about the business outlook for 2025. The Management Board anticipates sales growth for the group of 2.0 % to 5.0 %. Group EBIT is expected to be between EUR 53.0 mill. and EUR 64.0 mill.

For more information:

MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg
Germany

Investor Relations
Ender Gülcan
Phone +49 781/488-326
ender.guelcan@mediclin.de



www.mediclin.de

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 31 clinics, six care facilities and ten medical care centers. The group has around 8,200 beds/care places and employs around 9,900 people.
In a strong network, MEDICLIN offers the patients integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group
 


28.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MEDICLIN AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: ender.guelcan@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2108024

 
End of News EQS News Service

2108024  28.03.2025 CET/CEST

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2019 2020 2021 2022 2023 2024 2025e
Sales1 673,09 659,86 673,14 704,70 730,07 748,75 778,00
EBITDA1,2 93,58 77,50 85,22 90,92 98,73 103,77 115,00
EBITDA-Margin3 13,90 11,75 12,66 12,90 13,52 13,86 14,78
EBIT1,4 22,41 0,15 11,56 19,52 12,72 53,49 63,00
EBIT-Margin5 3,33 0,02 1,72 2,77 1,74 7,14 8,10
Net Profit (Loss)1 9,68 -0,04 1,49 9,72 -10,72 24,91 35,00
Net-Margin6 1,44 -0,01 0,22 1,38 -1,47 3,33 4,50
Cashflow1,7 69,59 118,69 81,97 34,64 78,00 50,57 74,00
Earnings per share8 0,20 -0,19 0,03 0,20 -0,23 0,52 0,74
Dividend per share8 0,05 0,00 0,00 0,00 0,00 0,04 0,04
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Mediclin
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
659510 DE0006595101 AG 179,55 Mio € 06.12.2000 Kaufen 8FW9FWGV+63
* * *
PE 2026e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
5,82 17,70 0,33 17,10 0,73 2,23 0,24
Dividends
Dividend '2023
in €
Dividend '2024
in €
Dividend '2025e
in €
Div.-Yield '2025e
in %
0,00 0,04 0,04 1,06%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
28.06.2026 04.05.2026 30.07.2026 04.11.2025 27.03.2026
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+0,00%
3,78 €
ATH 15,02 €
+12,80% +22,77% +56,20% +52,42% -65,64%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2025          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2025 by Gereon Kruse #BGFL